Pheochromocytoma and Neurofibromatosis Type 1 in a Patient with Hypertension
DOI:
https://doi.org/10.3889/oamjms.2015.130Keywords:
Pheochromocytoma, neurofibromatosis type 1, hypertension, antihypertensives, adrenalectomyAbstract
BACKGROUND: Neurofibromatosis type 1 is an autosomal dominant condition that has a variety of clinical manifestations. Essential or secondary hypertension may be associated with neurofibromatosis. A rare finding is hypertension due to pheochromocytoma in patient with neurofibromatosis type 1.
CASE REPORT: We present a case with a 7-year medical history of hypertension which was poorly controlled and with wide variations of blood pressure before the examination. Investigations did not reveal a secondary cause of hypertension. After the physical examination and establishing the diagnosis of neurofibromatosis, as well as the history of symptomes suggestive of catecholamine discharge, diagnostic procedures for pheochromocytoma were undertaken. Abdominal CT and MRI have proven the presence of a right adrenal tumor mass which was suspected to be a pheochromocytoma. Patient was preoperatively treated for two weeks with alpha and beta blokers and right adrenalectomy was performed. Perioperatively and on a longer term, blood pressure remained well controlled with less antihypertensive therapy. Diagnosis and management of pheochromocytoma in neurofibromatosis involves a dermatologist, endocrinologist, nephrologist and an urologist and requires a well-coordinated multidisciplinary approach.
CONCLUSIONS: Pheochromocytoma, although a rare condition in patients with neurofibromatosis, may be a cause for uncontrolled hypertension, as well as other cardiovascular complications and the clinician should do all available clinical investigations to confirm it or exclude it on time.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Group of authors. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45(5): 575-8. PMid:3128965 DOI: https://doi.org/10.1001/archneur.1988.00520290115023
Wallace MR, Marchuk DA, Anderson LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Bereton A, Nicholson J, Mitchell AL, Brownstein BH, Collins FS. Type 1 neurofibromatosis gene; identification of a larger transcript disrupted in three NF1 patients. Science. 1990;24:181–186. http://dx.doi.org/10.1126/science.2134734 DOI: https://doi.org/10.1126/science.2134734
Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genetics in Medicine. 2010;12:1–11.
http://dx.doi.org/10.1097/GIM.0b013e3181bf15e3 DOI: https://doi.org/10.1097/GIM.0b013e3181bf15e3
PMid:20027112
Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans G, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81–88.
http://dx.doi.org/10.1136/jmg.2006.045906 DOI: https://doi.org/10.1136/jmg.2006.045906
PMid:17105749 PMCid:PMC2598063
Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. Von Recklinghausen's disease and pheochromocytomas. J Urol. 1999;162:1582–6.
http://dx.doi.org/10.1016/S0022-5347(05)68171-2
Rocchietti March M, De Palma C, L'Angiocola PD, Aliberti G. Neurofibromatosis type I and hypertension: A case report. Recenti Prog Med. 2008;99:602–5.
PMid:19388218
Suzuki S. Ueber Zwei Tumoren aus Nebennierenmarkgewebe. Berlin Klein Wchnschr. 1910;47:1623.
Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. Von Recklinghausen's disease and pheochromocytomas. J Urol. 1999;162:1582–6. DOI: https://doi.org/10.1097/00005392-199911000-00003
http://dx.doi.org/10.1016/S0022-5347(05)68171-2 DOI: https://doi.org/10.1016/S0022-5347(05)68171-2
Boulkina LS, Newton CA, Drake III AJ, et al. Acute myocardial infarction attributable to adrenergic crises in patient with pheochromocytoma and neurofibromatosis 1. Endocr Pract. 2007;13: 269 -273.
http://dx.doi.org/10.4158/EP.13.3.269 DOI: https://doi.org/10.4158/EP.13.3.269
PMid:17599858
Darze ES, Von Sohsten RL. Pheochromocytoma – induced segmental myocardial dysfunction mimicking an acute myocardial infarction in a patient with normal coronary arteries. Arq Bras Cardiol. 2004;82:178-180. DOI: https://doi.org/10.1590/S0066-782X2004000200009
PMid:15042254
PSH Working Group: Diagnostic and treatment guidelines for patients with chromaffinoma. Nadciś Tętn. 2006;10:1-19.
Galati SJ, Said M, Gospin R, Babic N, Brown K, Geer EB, Kostakoglu L, Krakoff LR, Leibowitz AB, Mehta L, Muller S, Owen RP, Pertsemlidis DS, Wilck E, Xiao GQ, Levine AC, Inabnet WB 3rd.The mount Sinai clinical pathway for the management of pheochromocytoma. Endocr Pract. 2015;21:4,368-82.
http://dx.doi.org/10.4158/EP14036.RA DOI: https://doi.org/10.4158/EP14036.RA
PMid:25297659
Shinall MC, Solórzano CC. Pheochromocytoma in Neurofibromatosis Type 1: When Should it Be Suspected? Endocr Pract. 2014;20(8):792-6.
http://dx.doi.org/10.4158/EP13417.OR DOI: https://doi.org/10.4158/EP13417.OR
PMid:24518181
Rocchietti March M, De Palma C, L'Angiocola PD, Aliberti G. Neurofibromatosis type I and hypertension: A case report. Recenti Prog Med. 2008;99:602–5
PMid:19388218
Ahmed R, Darrat Y, Hamoudeh E, Elhamdani MO, Yaqub A. Acute cardiomyopathy and multiorgan failure in a patient with pheochromocytoma and neurofibromatosis type 1. J Pak Med Assoc. 2014;64(2):214-6. PMid:24640818
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0